1. Pharmacokinetics of imipenem-cilastatin following intravenous administration in healthy adult horses
- Author
-
Charles E. Benson, Robert H. Poppenga, Peter J. Moate, James A. Orsini, Raymond C. Boston, Tracy E. Norman, and Julie B. Engiles
- Subjects
Imipenem ,Dose ,Gram-positive bacteria ,Cilastatin, Imipenem Drug Combination ,Microbial Sensitivity Tests ,Pharmacology ,Gram-Positive Bacteria ,Pharmacokinetics ,Gram-Negative Bacteria ,Synovial Fluid ,polycyclic compounds ,medicine ,Animals ,Synovial fluid ,Horses ,Infusions, Intravenous ,Adverse effect ,General Veterinary ,Cilastatin ,biology ,business.industry ,Imipenem/cilastatin ,biology.organism_classification ,Anti-Bacterial Agents ,Drug Combinations ,Area Under Curve ,Anesthesia ,business ,medicine.drug - Abstract
In two studies, six healthy adult horses were given imipenem-cilastatin by slow intravenous (i.v.) infusion at an imipenem dosage of 10 mg/kg (study 1) and 20 mg/kg (study 2). The same horses were used in each dosage schedule, with a 2-week washout period between studies. In each dosage group, serial blood and synovial fluid samples were collected for 6 h after completion of the infusion. HPLC was used to determine the imipenem concentration in all samples. Imipenem was well tolerated by all horses at both dosages; no adverse effects were noted during the study period or during the 24-hour postinfusion observation period. The pharmacokinetic profiles of imipenem in the plasma and synovial fluid indicate that an imipenem dosage of 10-20 mg/kg by slow i.v. infusion q6h (every 6 h) is appropriate for most susceptible pathogens.
- Published
- 2005